Apply Now


Knowledge At MET

Knowledge At MET

Oncolytic Virotherapy: A Solution To Metastatic Cancer

Oncolytic Virotherapy is an emerging form of treatment for metastatic cancers.

It is a form of treatment which is under extensive research all round the globe and is a very prospective topic which is catching the eye of various researchers in the medical field.

It uses certain specific viruses called oncolytic viruses to tackle the issue of metastasis.

Research Studies

A great deal of research along with human clinical trials is being carried out for determining the feasibility and efficacy

of the treatment.

Many governmental and private medical institutions have shown interest in it and a lot of focus and attention is being given to it especially by the oncologists.

Institutions such as the Ottawa Hospital Research Institute, Canada; Jennerex Biotherapeutics ,San Francisco,USA have conducted a great in depth research on this subject along with many others.

Scope of Treatment

Metastatic cancer is the last stage of cancer in which the malignant and proliferating tumor cells spread from the

primary organ where they originated to other parts of the body and thus making the anti-cancer treatment all the more difficult to carry out.

Also more than 50% of the cancer cases which are detected are in this late metastatic stage thus increasing the mortality rate.

This treatment shows the promise and the plausibility of tackling this devastating form of cancer.

This therapy specifically involves a class of virus termed as picornavirus which has selective affinity for cancer cells. But like any other ground-breaking discovery there are certain hurdles that need to be overcome to make this treatment option a reality.

The above treatment option is currently under clinical trial and is usually combined with chemotherapy for optimum results.

Result and Review

Using Oncolytic Virotherapy alongwith certain other standard and non-standard treatment techniques it is possible to

provide a suitable cure for metastatic cancer and to reduce the mortality rate of cancer and enhance the longevity of life of cancer patients.

From this aforementioned piece of research evidence we intend to provide a possible solution to implement the above therapy by giving it a substantial backing and a scope for it to become a commercial success.

We would like to contribute to the ongoing research in this presentation work by applying whatever knowledge we have gained over the preceding years by presenting our solution to this long-standing problem of treating metastatic cancer.

Abhishek Nair, Dinesh Choudhary, Soumya Chikermane (T Y B Pharm)

Tags: MET Institute of Pharmacy